Pharmacoeconomics of low-molecular-weight heparins: Limitations of studies comparing them to unfractionated heparin

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 9, 2004, Pages 1887-1897

  Jones, Terry E ^a   Smith, Brian J ^a   Polasek, Jonathen Frederick ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Heparin; Heparin induced thrombocytopenia; Low molecular weight; Pharmacoeconomics; Unfractionated

Indexed keywords

ANTITHROMBOCYTIC AGENT; ARGATROBAN; DANAPAROID; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MONITORING; DRUG USE; ECONOMIC EVALUATION; GEOGRAPHY; HEMOPERITONEUM; HOSPITAL COST; HUMAN; MEDICOLEGAL ASPECT; MELENA; OUTPATIENT CARE; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG MONITORING; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 4544291027     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.9.1887     Document Type: Review

References (37)

1. TURPIE AGG, MASON JA: Review of enoxaparin and its clinical applications in venous and arterial thromboembolism. Expert Opin. Pharmacother. (2002) 3(5):575-598.
2. GEERTS WH, HEIT JA, CLAGETT GP et al.: Prevention of venous thromboembolism. Chest (2001) 119:132S-175S.
3. KLEBER F-X, WITT C, VOGEL G, KOPPENHAGEN K, SCHOMAKER U, FLOSBACH CW: Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease Am. Heart J. (2003) 145:614-621.
4. SIRAGUSA S, COSMI B, PIOVELLA F, HIRSCH J, GINSBERG JS: Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am. J. Med. (1996) 100:269-277.
5. QUINLAN DJ, MCQUILLAN A, EIKELBOOM JW: Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism; a meta-analysis of randomised, controlled trials. Ann. Intern. Med. (2004) 140:175-183.
6. COHEN M, DEMERS C, GURFINKEL EP et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N. Engl. J. Med. (1997) 337:447-452.
7. BERGQVIST D, for the ENOXACAN study group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind, randomized multicentre trial with venographic assessment Br. J. Surg. (1997) 84:1099-1103.
8. BORRIS LC, RUD LASSEN M: Thromboprophylaxis with low molecular weight heparin after major orthopaedic surgery is cost effective. Drugs (1996) 52(Suppl. 7):42-46.
9. DE LISSOVOY G, YUSEN R, SPIRO TE, KRUPSKI WC, CHAMPION AH, SORENSON SV: Cost for inpatient care of venous thrombosis: A trial of enoxaparin versus standard heparin. Arch. Intern. Med. (2000) 160:3160-3165.
10. HOMMES DW, BURA A, MAZZOLAI L, BULLER HR, TEN CATE JW: Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann. Intern. Med. (1992) 116:279-284.
11. ROOKE TW, OSMUNDSON PJ: Heparin and the in-hospital management of deep venous thrombosis: Cost considerations. Mayo Clin. Proc. (1986) 61:198-204.
12. RODGER M, BREDESON C, WELLS PS, BECK J, KEARNS B, HUEBSCH L: Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. Can. Med. Assoc. J. (1998) 159(8):931-938.
13. O'BRIEN B, LEVINE M, WILLAN A et al.: Economic evaluation of outpatient treatment with low-molecular-weight-heparin for proximal vein thrombosis. Arch. Intern. Med. (1999) 159(19):2298-2304.
14. ESTRADA CA, MANSFIELD CJ, HEUDEBERT GR: Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. J. Gen. Intern. Med. (2000) 15(2):108-115.
15. SMITH BJ, WEEKLEY JS, PILOTTO L, HOWE T, BEVEN R: Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin. Intern. Med. J. (2002) 32:29-34.
16. GOULD MK, DEMBITZER AD, SANDERS GD, GARBER AM: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann. Intern. Med. (1999) 130:789-799.
17. ANDERSON DR, O'BRIEN BJ, LEVINE MN, ROBERTS R, WELLS PS, HIRSCH J: Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann. Intern. Med. (1993) 119(11):1105-1112.
18. KAKKAR VV, COHEN AT, EDMONSON RA et al.: Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet (1993) 341:259-265.
19. SYNERGY TRIAL INVESTIGATORS: Enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. JAMA (2004) 292:45-54.
20. HULL RD RASKOB GE, PINEO GF et al.: Subcutaneous low-molecular-weight heparin compared with intravenous heparin in the treatment of proximal vein thrombosis. N. Engl. J. Med. (1992) 326:975-982.
21. HULL RD, RASKOB GE, ROSENBLOOM D et al.: Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin versus intravenous heparin: an economic perspective. Arch. Intern. Med. (1997) 157(3):289-294.
22. DAGER WE, WHITE RH: Pharmacotherapy of heparin-induced thrombocytopenia. Expert Opin. Pharmacother. (2003) 4(6):919-940.
23. WARKENTIN TE, ROBERTS RS, HIRSCH J, KELTON JG: An improved definition of immune heparin-induced thrombocytopaenia in postoperative orthopaedic patients. Arch. Intern. Med. (2003) 163:2518-2524.
24. WARKENTIN TE, KELTON JG: A 14-year study of heparin-induced thrombocycopenia. Am. J. Med. (1996) 101:502-507.
25. SMYTHE MA, WARKENTIN TE, STEPHENS JL, ZAKALIK D, MATTSON JC: Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am. J. Haematol. (2002) 71:50-52.
26. GREINACHER A, LUBENOW N: Recombinant hirudin in clinical practice. Focus on lepirudin. Circulation (2001) 103:1479-1484.
27. WARKENTIN TE, KELTON JG: Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. (2001) 344:1286-1292.
28. WARKENTIN TE: Platelet count monitoring and laboratory testing for heparin-induced thrombocyropenia: recommendations for the College of American Pathologists. Arch. Pathol. Lab. Med. (2002) 126:1415-1423.
29. HULL RD, RASKOB GE, PINEO GF et al.: Subcutaneous low-molecular-weight heparin versus warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation: an economic perspective. Arch. Intern. Med. (1997) 157(3):298-303.
30. O'BRIEN BJ, WILLAN A, BLACKHOUSE G, GOEREE R, COHEN M, GOODMAN S: Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am. Heart. J (2000) 139(3):423-429.
31. SCHULMAN S: Unresolved issues in anticoagulant therapy. J. Thromb. Haemostasis (2003) 1:1464-1470.
32. SANDERINK G-J, LIBOUX AL, JARIWALA N et al.: The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin. Pharmacol. Ther. (2002) 72:308-318.
33. SPINLER SA, INVERSO SM, COHEN M, GOODMAN SG, STRINGER KA, ANTMAN EM: Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with sever renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am. Heart. J. (2003) 146:33-41.
34. SANDERINK GJCM, GUIMART CG, OZOUX ML, JARIWALA NU, SHUKLA UA, BOUTOUYRIE BX: Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb. Res. (2002) 105:225-231.
35. BECKER RC, SPENCER FA, GIBSON M et al.: Influence of patient characteristics and renal function on Factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am. Heart J. (2002) 143:753-759.
36. WAN S, TING J, OLSEN A, CROSER J, EIKELBOOM JW: Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western Australia. ANZ J. Surg. (2003) 73:826-829.
37. SWAN J, SPIGELMAN AD: Audit of surgeon awareness of readmissions with thrombo-embolism. Intern. Med. J. (2003) 33:578-580.